Life Sciences

2020 healthcare and life sciences investment outlook

Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.

The Race to EU MDR Compliance Continues

Despite progress, companies are still facing many questions

Quality 2030

Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator

Medical device regulatory affairs operational transformation

Key insights and opportunities to unlock additional value by streamlining Regulatory Affairs operational activities

An open target

Despite progress in corporate cybersecurity, life sciences operational technology is still vulnerable to increasingly sophisticated threats.

Global lessons in building a continuous improvement culture in healthcare

Building a culture of excellence in healthcare

Embracing transparency

Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.

Prescription drug rebates

Proposed safe harbor changes open for comment

Part D Payment Modernization Model

Consider applying for the voluntary initiative

Driving value from genomics in Life Sciences

Rising to the data challenge

Opportunities in an evolving market

2019 Health Care & Life Sciences Investment Outlook

R&D 2030

Reinvent innovation and become an R&D front-runner by 2030

Digital transformation in regulatory affairs

Unlocking value for life sciences organizations

Pharmaceuticals industry exec summary - Harvey Nash/KPMG CIO survey 2018

This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.

The race to EU MDR compliance

KPMG/RAPS survey illustrates the ground medical device companies still have to cover

Insider threat in life sciences

2018 Program benchmark report

Digital health and disruption in diabetes

Identifying opportunities for life sciences manufacturers.

Future of finance: Finance disrupted

Innovation in the life sciences finance function

The disruption challenge

As new entrants and cross-sector models abound, which direction should healthcare organizations turn?

Demystifying blockchain for life sciences

Blockchain could be a key to interoperability and privacy

Revenue for the life sciences industry

New standard. New challenges.

2018 Health care & life sciences investment outlook

Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.

Top trends and risks for 2018

Navigating a transforming life sciences landscape

Personalized care requires personal data

GDPR in Life Sciences Reference Card

The future of oncology:

A focused approach to winning in 2030